Leishmania transmission-blocking vaccines: a review.
To review information on transmission-blocking vaccine against Leishmania infections. Peer-reviewed journals and accepted manuscripts in press. Laboratory studies based on raising of immune sera against Leishmania-derived antigens using the BALB/c and hamster murine models. Testing of the immune sera for their potential to limit the transmission of cutaneous leishmaniasis in its natural vector Phlebotomus duboscqi. Leishmania major-derived recombinant 63 kilodalton glycoprotein (rgp63), lipophosphoglycan (LPG), whole parasite, flagella and nuclear fractions; monoclonal antibodies and sandfly gut antigens have all been tested for their candidacy as Leishmania-transmission blocking vaccines. Liposphoglycan proved to be a promising candidate for Leishmania transmission-blocking vaccine studies.